<DOC>
	<DOCNO>NCT00002373</DOCNO>
	<brief_summary>To evaluate safety tolerability multiple escalating dose 1263W94 administer orally 28 day HIV infect patient asymptomatic CMV shed . To obtain preliminary evidence vivo anti CMV activity different dose 1263W94 human base quantitative reduction CMV load semen possible biological fluid explore dose response relationship anti-CMV activity 1263W94 .</brief_summary>
	<brief_title>The Safety Effectiveness Different Dose Levels 1263W94 Treatment Cytomegalovirus ( CMV ) Eyes HIV-Infected Patients</brief_title>
	<detailed_description>HIV seropositive men stratify base CMV titer semen Pre-Screen visit ( 30 day prior entry ) . Patients CMV titer &gt; = 5000 PFU/ml positive result upon qualitative urine CMV culture may eligible entry main group patient CMV titer &lt; 5000 PFU/ml may eligible entry satellite group . Patients 1263W94 4 week . Patients present clinic visit study day 1 , 7 , 14 , 21 , 28 . They return clinic post treatment evaluation study day 42 56 .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Stable , chronically administer concomitant therapy HIV infection opportunistic disease patient regimen least one month prior study entry . Patients must : Required Main group : Minimum CMV titer 5000 PFU/ml semen quantitative CMV culture one occasion within 30 day entry . Demonstrating positive result qualitative CMV culture urine one occasion within 30 day entry . Required Satellite group : Must CD4+ &lt; 150 c/mm3 ( 10 % total lymphocyte ) screen . Required group : HIV infection . Life expectancy &gt; 6 month . Able comply protocol requirements/instructions likely complete study visit evaluation plan . Prior Medication : Allowed : Stable , chronically administer concomitant therapy HIV infection opportunistic disease least one month prior . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Active CMV disease ( retinitis , colitis , encephalitis , pneumonitis , etc. ) . Visual symptom sign suggestive CMV disease ( e.g. , floater , visual field defect , decrease visual acuity ) ; Unless CMV disease exclude via ophthalmoscopy examination . Active hepatitis , obstructive hepatobiliary disease cirrhosis . Gastrointestinal disorder , judgement investigator , might interfere oral dose drug absorption may indicative CMV disease e.g. , chronic nausea vomiting , active bowel disease persistent diarrhea . Diagnosis chronic disease diabetes hypoglycemia , epilepsy , ongoing Grade II peripheral neuropathy , congestive heart failure , cardiomyopathy , organ dysfunction , etc. , opinion investigator , would compromise safety compliance patient . Participation investigational trial . Patients debilitate result HIV disease associate illness therapy , investigator 's opinion , condition may interfere study assessment patient 's ability complete entire study per protocol requirement . Concurrent Medication : Excluded : Systemic therapy visceral malignancy . Concurrent Treatment : Excluded : Treatment radiation therapy visceral malignancy . Patients follow prior symptom condition exclude : History CMV disease ( retinitis , colitis , encephalitis , pneumonitis , etc . ) Known history lactose intolerance . Prior Medication : Excluded : Systemic therapy visceral malignancy within 2 month prior entry . Prior treatment ganciclovir , foscarnet , cidofovir , investigational antiCMV drug ( e.g. , intravenous acyclovir , lobucavir , valacyclovir ) within 2 month prior entry . Treated interferon , immunomodulators CMV hyperimmune globulin within 1 month prior entry . Any investigational therapy within 1 month prior study entry . Prior Treatment : Excluded : Treatment radiation therapy visceral malignancy within 2 month prior entry . Treatment investigational treatment within 1 month study entry .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 1998</verification_date>
	<keyword>Cytomegalovirus</keyword>
	<keyword>Cytomegalovirus Infections</keyword>
	<keyword>Administration , Oral</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Virus Shedding</keyword>
	<keyword>Viral Load</keyword>
</DOC>